Stocks
Anika Therapeutics Financial Statements (ANIK) |
||||||||||
| Anika Therapeuticssmart-lab.ru | % | 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 05.03.2021 | 11.03.2022 | 16.03.2023 | 31.12.2023 | 15.03.2024 | 08.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 130.5 | 147.8 | 156.2 | 166.7 | 166.7 | 169.3 | |||
| Operating Income, bln rub | -14.5 | -18.5 | -19.4 | -25.4 | -25.4 | -18.0 | ||||
| EBITDA, bln rub | ? | -0.614 | -39.6 | -19.4 | -18.4 | -11.2 | -8.22 | |||
| Net profit, bln rub | ? | -24.0 | 4.13 | -14.9 | -82.7 | -82.7 | -76.8 | |||
| OCF, bln rub | ? | 13.1 | 8.40 | 4.41 | -1.79 | 1.70 | ||||
| CAPEX, bln rub | ? | 1.63 | 5.14 | 7.49 | 5.43 | 5.85 | ||||
| FCF, bln rub | ? | 11.4 | 3.25 | -3.08 | -7.22 | -4.14 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 83.5 | 101.4 | 113.0 | 128.5 | 128.5 | 122.8 | ||||
| Cost of production, bln rub | 61.4 | 64.9 | 62.7 | 63.6 | 63.6 | 64.4 | ||||
| R&D, bln rub | 23.4 | 27.3 | 28.2 | 32.7 | 32.7 | 32.5 | ||||
| Interest expenses, bln rub | 0.302 | 0.188 | 0.654 | 0.000 | 2.31 | 2.37 | ||||
| Assets, bln rub | 365.6 | 347.5 | 349.1 | 270.6 | 270.6 | 263.7 | ||||
| Net Assets, bln rub | ? | 272.4 | 287.1 | 285.6 | 212.3 | 212.3 | 208.5 | |||
| Debt, bln rub | 20.9 | 19.2 | 30.9 | 26.9 | 29.0 | 28.5 | ||||
| Cash, bln rub | 98.3 | 94.4 | 86.3 | 72.9 | 72.9 | 68.6 | ||||
| Net debt, bln rub | -77.4 | -75.1 | -55.4 | -46.0 | -43.8 | -40.2 | ||||
| Ordinary share price, rub | 45.3 | 35.8 | 29.6 | 22.7 | 22.7 | 20.0 | ||||
| Number of ordinary shares, mln | 14.2 | 14.4 | 14.6 | 14.7 | 14.7 | 14.7 | ||||
| Market cap, bln rub | 644 | 516 | 431 | 332 | 332 | 294 | ||||
| EV, bln rub | ? | 566 | 441 | 376 | 286 | 288 | 254 | |||
| Book value, bln rub | 173 | 197 | 204 | 205 | 200 | 197 | ||||
| EPS, rub | ? | -1.69 | 0.29 | -1.02 | -5.64 | -5.64 | -5.23 | |||
| FCF/share, rub | 0.80 | 0.23 | -0.21 | 0.00 | -0.49 | -0.28 | ||||
| BV/share, rub | 12.2 | 13.7 | 14.0 | 14.0 | 13.7 | 13.4 | ||||
| EBITDA margin, % | ? | -0.47% | -26.8% | -12.4% | -11.0% | -6.73% | -4.86% | |||
| Net margin, % | ? | -18.4% | 2.80% | -9.51% | -49.6% | -49.6% | -45.4% | |||
| FCF yield, % | ? | 1.78% | 0.63% | -0.71% | 0.00% | -2.17% | -1.41% | |||
| ROE, % | ? | -8.80% | 1.44% | -5.20% | -38.9% | -38.9% | -36.8% | |||
| ROA, % | ? | -6.56% | 1.19% | -4.26% | -30.5% | -30.5% | -29.1% | |||
| P/E | ? | -26.8 | 124.8 | -29.0 | -4.02 | -4.02 | -3.83 | |||
| P/FCF | 56.3 | 158.6 | -140.1 | -46.0 | -71.0 | |||||
| P/S | ? | 4.93 | 3.49 | 2.76 | 1.99 | 1.99 | 1.74 | |||
| P/BV | ? | 3.72 | 2.62 | 2.12 | 1.62 | 1.66 | 1.49 | |||
| EV/EBITDA | ? | -922.2 | -11.1 | -19.4 | -15.6 | -25.7 | -30.9 | |||
| Debt/EBITDA | 126.1 | 1.90 | 2.86 | 2.50 | 3.91 | 4.89 | ||||
| R&D/CAPEX, % | 1 439% | 531.3% | 376.5% | 602.4% | 555.1% | |||||
| CAPEX/Revenue, % | 1.25% | 3.48% | 4.79% | 0.00% | 3.26% | 3.45% | ||||
| Anika Therapeutics shareholders | ||||||||||
